# Terrapin Urges State Action After DOJ Medical Marijuana Rescheduling > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/doj-medical-marijuana-rescheduling-impact-state-action/ > **Published:** 2026-04-26T02:06:40-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:10:26-04:00 > **Clinical Summary:** Explore the DOJ medical marijuana rescheduling impact and how it calls for state action to improve medical cannabis access and research opportunities. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Federal Policy[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)RegulationResearch AccessSchedule Iii Why This Matters Federal rescheduling from Schedule I to Schedule III would fundamentally alter the regulatory landscape for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), potentially improving research access and reducing banking barriers that currently complicate [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-review/). This shift could enable more rigorous clinical studies and streamline [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to medical cannabis programs. Clinical Summary The DOJ’s proposed rescheduling of cannabis from Schedule I to Schedule III represents the most significant federal policy change regarding medical cannabis in decades. Schedule III classification acknowledges accepted medical use while maintaining controlled substance status, similar to ketamine or anabolic steroids. This change would remove the research barriers imposed by Schedule I status and could reduce the 280E tax burden that inflates medical cannabis costs. However, it does not change state-level medical cannabis programs or federal prescription requirements. Dr. Caplan’s Take “This rescheduling is long overdue from a clinical standpoint—we’ve been treating patients effectively with cannabis while operating under an outdated classification that called it medically useless. The real question now is whether states will adapt their programs to maximize the clinical benefits this federal shift enables.” Clinical Perspective 🧠 Clinicians should expect potential changes in research availability and possibly improved product consistency as federal oversight mechanisms develop. Patients in existing state programs should not expect immediate changes to access or protocols, but may see cost reductions over time. The rescheduling does not create a pathway for FDA-approved cannabis prescriptions in the near term. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Terrapin%20calls%20for%20state%20action%20following%20DOJ%E2%80%99s%20medical%20marijuana%20rescheduling%20%7C%20News%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fterrapin-calls-for-state-action-following-doj-s-medical-marijuana-rescheduling-n%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fterrapin-calls-for-state-action-following-doj-s-medical-marijuana-rescheduling-n%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Terrapin%20calls%20for%20state%20action%20following%20DOJ%E2%80%99s%20medical%20marijuana%20rescheduling%20%7C%20News%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fterrapin-calls-for-state-action-following-doj-s-medical-marijuana-rescheduling-n%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.northcentralpa.com/news/terrapin-calls-for-state-action-following-doj-s-medical-marijuana-rescheduling/article_2dadcc61-7fe5-4139-816f-97b100d513b3.html](https://www.northcentralpa.com/news/terrapin-calls-for-state-action-following-doj-s-medical-marijuana-rescheduling/article_2dadcc61-7fe5-4139-816f-97b100d513b3.html) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news update?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news_update) - [What type of cannabis-related content does this update cover?](#What_type_of_cannabis-related_content_does_this_update_cover) - [Why is this cannabis news considered clinically relevant?](#Why_is_this_cannabis_news_considered_clinically_relevant) - [What areas of cannabis policy does this update address?](#What_areas_of_cannabis_policy_does_this_update_address) - [How should healthcare professionals interpret this clinical relevance rating?](#How_should_healthcare_professionals_interpret_this_clinical_relevance_rating) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news update? This update has been assigned CED Clinical Relevance #76, indicating “Notable Clinical Interest.” This rating signifies emerging findings or policy developments that are worth monitoring closely by [healthcare professionals](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). #### What type of cannabis-related content does this update cover? This update focuses on federal policy developments related to medical cannabis. It appears to address regulatory changes and research access issues at the federal level. #### Why is this cannabis news considered clinically relevant? The update is marked as having “Notable Clinical Interest” because it involves emerging policy developments that could impact medical cannabis practice. Federal policy changes can significantly affect how healthcare providers prescribe and patients access medical cannabis. #### What areas of cannabis policy does this update address? The update covers multiple key areas including federal policy changes, medical cannabis regulations, and research access provisions. These interconnected topics are crucial for understanding the evolving landscape of medical cannabis. #### How should healthcare professionals interpret this clinical relevance rating? A rating of #76 with “Notable Clinical Interest” suggests this is an emerging development that warrants attention but may not require immediate action. [Healthcare professionals](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) should monitor these developments as they could influence future practice guidelines and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-review/) options. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Rescheduling of FDA Approved Marijuana Products](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) Detailed overview of the FDA-approved marijuana products rescheduling from Schedule I to Schedule III and related permit changes. [Read More](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) [Trump Administration Officially Reclassifies State-Licensed Medical Marijuana](https://cedclinic.com/federal-cannabis-schedule-iii-research-policy-update/) Insights into the Trump administration’s official reclassification of [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) as a Schedule III drug. [Learn More](https://cedclinic.com/federal-cannabis-schedule-iii-research-policy-update/) [Justice Department Plans Could Ease Medical Marijuana Restrictions](https://cedclinic.com/cannabis-research-regulatory-changes-rochester-lab/) Explore how DOJ plans may reduce restrictions and improve research access for [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). [Explore Now](https://cedclinic.com/cannabis-research-regulatory-changes-rochester-lab/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).